A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
ESTRADIOL
Test CodeLAB523
CPT Codes
82670
Preferred Specimen
One 4.5 mL light green top tube
Pediatric: One light green top microtainer
Pediatric: One light green top microtainer
Other Acceptable Specimens
Red top tube, or gold top tube
Instructions
Limitation for the Estradiol: Estradiol results from this method (Abbott immunoassay) are falsely and dramatically elevated in patients taking mifepristone (RU-486) for up to 2 weeks, based on the bioavailability of this compound. Please contact thechemistry laboratory with questions.
Sample must be centrifuged within two hours of collection. Serum/plasma must be removed from the red cells and put into aliquot tubes following centrifugation.
Sample must be centrifuged within two hours of collection. Serum/plasma must be removed from the red cells and put into aliquot tubes following centrifugation.
Transport Container
\
Transport Temperature
Refrigerated
Specimen Stability
Centrifuge within 2 hours after collection
Ambient: 24 hours Refrigerated: 7 days Frozen: not specified
Ambient: 24 hours Refrigerated: 7 days Frozen: not specified
Methodology
Chemiluminescent Immunoassay
Setup Schedule
Sunday-Saturday
Reference Range
Males | <24-44 pg/mL |
Females | |
Follicular | <24-251 pg/mL |
Peri-ovulatory | 38-649 pg/mL |
Mid-luteal | <24-312 pg/mL |
Postmenopausal (on HRT) | <24-144 pg/mL |
Postmenopausal (not on HRT) | <24-28 pg/mL |
Clinical Significance
- Evaluating hypogonadism and oligo-amenorrhea in females
- Assessing ovarian status, including follicle development, for assisted reproduction protocols
- Monitoring of estrogen replacement therapy in hypogonadal premenopausal women in conjunction with LH
- Evaluating feminization, including gynecomastia, in males
- Diagnosing estrogen-producing neoplasms in males, and, to a lesserdegree, females
- As part of evaluation of precocious and delayed puberty in females, and, to a lesser degree, males
- As part of evaluation of suspected disorders of sex steroid metabolism, eg, aromatase deficiency and 17 alpha-hydroxylase deficiency
- As an adjunct to clinical assessment, imaging studies and bone mineral density measurement in the fracture risk assessment of postmenopausal women, and, to a lesser degree, older men
- Monitoring low-dose female hormone replacement therapy in postmenopausal women
- Monitoring antiestrogen therapy (eg, aromatase inhibitor therapy)
Performing Laboratory
West Virginia University Hospital, Inc.
Berkeley Medical Center Camden Clark Medical Center United Hospital Center Wheeling Hospital